© MGP Ltd 2017







Implementing the BSACI guideline for the diagnosis and management of allergic and non-allergic rhinitis¹

Epidemiology

- Allergic rhinitis affects 10–15% of children and 26% of adults in the UK
- It has a significant impact on quality of life, and interferes with performance and attendance at school and work
- Rhinitis is strongly associated with asthma—around 74–81% of people with asthma report symptoms of rhinitis

Classification

Allergic rhinitis

- · Symptoms are caused by IgE-mediated reaction to allergens
- Can be further classified into seasonal and perennial rhinitis (this is useful for diagnosis and allergen-specific therapy)
- · A positive diagnosis is more likely in patients with symptoms of sneezing, nasal itching, or itching of the palate

Non-allergic rhinitis

- Symptoms of rhinitis that have no identifiable allergic triggers
- · Diagnosis is confirmed by exclusion in cases negative for systemic IgE, when other causes of rhinitis have been ruled out

Symptoms
Rhinorrhoea (anterior, posterior, or both) Nasal obstruction (partial or complete): bilateral—likely due to rhinitis but consider nasal polyps or septal deviation unilateral—consider septal deviation, foreign body, antrochoanal polyp, and tumours Nasal crusting (NB severe crusting, especially high inside the nose, is unusual in rhinitis): consider chronic rhinosinusitis, nose picking, or cocaine abuse Eye symptoms (intense itching, redness, swelling of white of the eye, lid swelling, periorbital oedema [in severe cases]) Lower respiratory tract symptoms: cough, wheeze, and shortness of breath Other symptoms: snoring, sleep problems, repeated sniffing, nasal intonation of voice pollen—food syndrome triggered by cross-reacting ingested allergens
Diagnosis
Take a detailed history, including: seasonality work location (occupational rhinitis) presence of house pets indoors or outdoors location any improvement of symptoms on holidays family history of rhinitis relationship to potential triggers (including drugs) Perform a visual examination, taking note of any of the following clinical features: horizontal nasal crease chronic mouth breathing obstructed nasal airflow altered nasal bridge Perform an anterior rhinoscopy, taking note of any of the following clinical features: hypertrophic, pale, and boggy inferior or middle turbinates presence of secretions or polyps throat appearance—cobblestoned, lymphoid hyperplasia, post-nasal drip septal perforation Investigate the presence of allergen-specific IgE: use a skin prick test, or measure serum-specific IgE or total IgE use other laboratory investigations if necessary, based on history, examination, and result of skin prick testing
Treatment*
Advise patient to avoid allergens as far as practically possible Consider isotonic saline irrigation—this may reduce the amount of pharmacotherapy required Consider carbon dioxide washing—this can reduce all the symptoms of rhinitis within minutes Use a stepwise pharmacotherapeutic approach (a combination of treatments is often required for severe disease)



Treatment* (continued) H,-antihistamines Offer first line for mild-to-moderate intermittent rhinitis and mild persistent rhinitis Oral H₁-antihistamines: should be used regularly rather than 'as needed' acrivastine has the fastest onset of action, but needs to be taken every 8 hours fexofenadine is the least sedating oral antihistamine add to INS for treatment of moderate or severe persistent rhinitis that is uncontrolled on topical INS alone, particularly when eye symptoms are present Topical intranasal H₁-antihistamines: - faster onset of action than oral antihistamines (15 minutes), and superior relief of rhinitis symptoms less effective than INS in relieving allergic rhinitis symptoms use continuously or on demand for breakthrough symptoms add to INS for treatment of moderate or severe persistent rhinitis that is uncontrolled on topical INS alone **Intranasal corticosteroids** Effective mainstay of inflammatory intervention in allergic rhinitis Offer first line for moderate to severe persistent rhinitis Offer first line for severe nasal obstruction, possibly combined with a short-term nasal decongestant (NB steroid drops or oral steroids should be used initially for up to 1 week) Advise patient that clinical improvement may not be apparent for a few days Start treatment 2 weeks prior to known allergy season to improve efficacy **Combination therapy** Use a combination of topical antihistamine with INS if symptoms remain uncontrolled on either antihistamine or INS monotherapy, or on a combination of oral antihistamine with INS Intranasal decongestants Use to relieve nasal congestion—only short-term use of up to 10 days is recommended Use to increase nasal patency to allow delivery of drugs beyond inferior turbinates Can be offered to patients with seasonal allergic rhinitis and concomitant asthma **Topical anti-cholinergic** Consider use if watery rhinorrhoea symptoms persist despite compliance with INS monotherapy or INS with antihistamine Chromones Can be used to treat rhinitis symptoms in patients who are unable to take other medications (e.g. pregnant women) Useful to treat conjunctivitis **Ocular therapy** Oral antihistamines and intranasal agents can suppress ocular manifestations of seasonal rhinoconjunctivitis · Immunotherapy, where indicated, can also be effective for eye symptoms Ensure that use of topical steroids to treat eye symptoms is supervised by an ophthalmologist Advise patient that wearing sunglasses reduces eye symptoms **Immunotherapy** · Can improve symptoms, reduce medication requirements, and improve quality of life Subcutaneous injection immunotherapy is effective for seasonal rhinitis due to pollens Sublingual immunotherapy is an effective treatment for allergic rhinitis caused by certain allergens **Treatment of non-allergic rhinitis**

- Base treatment choice on nasal smear examination
- If there is inflammation, use anti-inflammatory therapy
- If there is no inflammation, use anti-cholinergic therapy or capsaicin

 $BSACI=British\ Society\ for\ Allergy\ and\ Clinical\ Immunology;\ IgE=immunoglobulin\ E;\ INS=intranasal\ corticosteroid\ Section 1.$

- * Refer to the full guideline¹ and the individual summaries of product characteristics for further information and recommendations regarding the use of pharmacological therapies
- 1. Scadding GK, Kariyawasam H, Scadding G et al. BSACI guideline for the diagnosis and management of allergic and non-allergic rhinitis (Revised Edition 2017; First edition 2007). Clin Exp Allergy 2017; 47: 856–889.

